# US Artificial Retina Market > US Artificial Retina Market Research Report: Size, Share, Trend Analysis By Product (Enzymes, Pharma Products, Bulk Chemicals, Others), By Applications (Bioengineering, Genomics, Vaccine Development, Drug Discovery, Fisheries, Aquaculture, Biofuels, Water Treatment Services, Others) and By End Users (Hospitals, Pharmaceutical Companies, Biotechnology Companies, Others) - Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 8.41% - **2024:** $ 501.29 Million - **2025:** $ 543.45 Million - **2035:** $ 1,218.81 Million - **Key Players:** Second Sight Medical Products (US), Pixium Vision (FR), Bionic Vision Technologies (AU), Retina Implant AG (DE), Elekta (SE), Nidek Co Ltd (JP), Abbott Laboratories (US), Alcon (CH) **Report ID:** MRFR/MED/17439-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-artificial-retina-market-18985 --- ## Market Summary ## **US Artificial Retina Market Overview** As per MRFR analysis, the US Artificial Retina Market Size was estimated at 214.82 (USD Million) in 2023. The US Artificial Retina Market Industry is expected to grow from 300 (USD Million) in 2024 to 2,800 (USD Million) by 2035. The US Artificial Retina Market CAGR (growth rate) is expected to be around 22.514% during the forecast period (2025 - 2035). ### **Key Market Trends Highlighted** The US Artificial Retina Market is experiencing notable trends driven by advancements in technology and increasing prevalence of retinal diseases. One key market driver is the growing aging population in the country, as age-related macular degeneration and diabetic retinopathy are leading causes of vision loss among older adults. The National Eye Institute indicates that the number of individuals affected by these eye conditions is expected to rise significantly in the coming years, creating a higher demand for effective treatment options such as artificial retina devices. Recent developments include innovations in device design and functionality. Companies are focusing on enhancing the resolution and ease of use of artificial retinas, allowing for better integration into patients' daily lives. Furthermore, partnerships between technology firms and healthcare organizations pave the way for new research and clinical trials. This collaborative approach aims to improve device performance and expand the range of treatable conditions, thereby addressing unmet medical needs in the US market. Additionally, there are abundant opportunities for growth as regulatory pathways for approval become clearer, encouraging more players to enter the market. Increased investment in research and development, supported by government initiatives and grants for ophthalmic research, further amplifies this potential. The trend towards personalized medicine also offers opportunities for customizing artificial retina devices to better fit individual patient needs, thereby enhancing their effectiveness. This shift may lead to more tailored solutions that improve outcomes for patients battling vision impairment in the US. Overall, the confluence of these elements is fostering a dynamic environment for development and innovation within the US Artificial Retina Market. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **US Artificial Retina Market Drivers** ### **Increasing Prevalence of Retinal Disorders** The US Artificial Retina Market Industry is significantly driven by the rising prevalence of retinal disorders such as retinitis pigmentosa and age-related macular degeneration (AMD). According to the American Academy of Ophthalmology, approximately 2.1 million Americans aged 50 and older have AMD, and projections suggest this number will increase to nearly 3 million by 2025. This intensifying patient base emphasizes the necessity for innovative treatment options such as retinal implants. Established organizations like the National Eye Institute are actively promoting awareness and funding Research and Development for artificial retina technologies, which in turn fuels the growth of the US [Artificial Retina](../../../reports/artificial-retina-market-2812) Market. With an increasing aging population and advancements in technology, the demand for artificial retina devices is expected to grow substantially, fostering a healthier quality of life for patients suffering from vision loss. ### **Technological Advancements in Device Development** The growth of the US Artificial Retina Market Industry is bolstered by the rapid technological advancements in the development of retinal prostheses. Innovations such as wireless systems and enhanced visual acuity technologies are being developed by key players including Second Sight Medical Products, which has made significant progress with the Argus II Retinal Prosthesis System. The National Institutes of Health has pointed out that ongoing Research and Development efforts in the field have led to notable improvements in device efficacy and patient outcomes, which has encouraged further investment in artificial retina technologies. These advancements not only improve the performance of artificial retina devices but also expand their applicability, attracting more patients and healthcare providers to consider these solutions. ### **Increased Funding for Research and Development** The US Artificial Retina Market Industry is experiencing substantial growth due to increased funding for Research and Development initiatives aimed at finding solutions for visual impairments. U.S. federal funding has seen a significant rise in the budget allocations for vision-related Research and Development, with the National Eye Institute reporting an increase in funding to approximately 800 million USD in recent years. This financial support has catalyzed the advancement of artificial retina technologies, attracting both public and private investments. With major institutions like Stanford University and Johns Hopkins University actively pursuing this research, the enhanced focus on developing effective retinal implants drives the growth of the US Artificial Retina Market, promising innovative treatments to millions affected by retinal diseases. ### **Growing Awareness of Vision Health** The rising awareness regarding vision health in the United States is a significant driver of the US Artificial Retina Market Industry. Campaigns led by organizations such as the American Optometric Association have resulted in increased public understanding of retinal diseases and the available treatment options. Moreover, the Centers for Disease Control and Prevention have reported that around 61 million adults in the U.S. are at high risk for serious vision loss, prompting efforts to emphasize the importance of regular eye examinations. As more people become aware of the benefits of artificial retina technology, coupled with the endorsement from established organizations and healthcare providers, the demand for such devices is likely to surge, propelling the US Artificial Retina Market's growth. ## **US Artificial Retina Market Segment Insights** ### **Artificial Retina Market Product Insights** The US Artificial Retina Market focuses on various product segments, including Enzymes, Pharma Products, Bulk Chemicals, and Others, each playing a crucial role in the development and improvement of artificial retina technologies. Enzymes are essential in the biological processes involved in retinal restoration and may help enhance the efficacy of the artificial devices, leading to more effective treatment options for retinal disorders. On the other hand, Pharma Products represent a vital aspect of this market, contributing to the therapeutic offerings that complement artificial retina solutions. They can assist in managing the underlying conditions that lead to vision loss, thereby ensuring a comprehensive approach to treatment. Bulk Chemicals, while not directly involved in the end-product development, serve as crucial materials in the manufacturing of various components of artificial retinal devices. The use of these chemicals can influence the production costs and the overall quality of the devices. Lastly, the Others category encompasses additional innovative products and technologies that do not fit into the conventional classifications but are essential for advancing the US Artificial Retina Market. This category could include next-generation materials and emerging therapies that leverage technological advancements in the field. Overall, the ongoing technological developments and the growing prevalence of retinal diseases in the United States are likely to propel the demand for these products, driving the market growth and offering significant opportunities for stakeholders involved in the US Artificial Retina Market. Market statistics indicate that each of these product types contributes distinctly to the overall market dynamics, influencing the competitive landscape and prompting innovations that cater to the diverse needs of patients suffering from vision impairments. Moreover, as the focus on personalized medicine and patient-centered care intensifies, each segment is expected to experience significant advancements that will enhance treatment outcomes and optimize patient experiences. Healthcare in the US is increasingly recognizing the importance of integrating these products into therapeutic strategies, promoting collaborations between pharmaceutical companies and research institutions to drive the next wave of advancements in artificial retina technology. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Artificial Retina Market Application Insights** The Application segment of the US Artificial Retina Market showcases a diverse range of fields, each contributing to innovative advancements in healthcare and environmental sustainability. Bioengineering stands out as a crucial area, focusing on the integration of biological principles with engineering technologies to develop effective solutions for vision restoration. Genomics plays a vital role, providing insights into genetic factors influencing eye diseases, which can lead to personalized treatment strategies. Vaccine Development and Drug Discovery are essential for enhancing retinal health, as they contribute to the prevention and treatment of retinal disorders through innovative therapies. The significance of Fisheries and Aquaculture emerges in the context of maintaining aquatic ecosystems, where artificial retina technologies can help monitor and improve fish health and biodiversity. In the realm of Biofuels, advancements can drive the development of sustainable energy sources that can power medical devices. Water Treatment Services are increasingly important to ensure clean water supplies, influencing ocular health. Overall, these areas illustrate the broad applicability of artificial retina technologies across various sectors, supporting a healthier population and a sustainable environment in the US. The ongoing growth in these areas signifies strong potential for technological breakthroughs and market expansion, reflecting broader trends in the US Artificial Retina Market revenue and its overall statistics. ### **Artificial Retina Market End User Insights** The US Artificial Retina Market is characterized by a diverse array of end users, primarily including hospitals, pharmaceutical companies, biotechnology companies, and others. Hospitals play a crucial role as they are key providers of healthcare services, offering essential infrastructure for artificial retina implantation and related treatments. Their contributions significantly influence market dynamics as they adopt advanced technologies to improve patient outcomes. Pharmaceutical and biotechnology companies are equally vital, as they drive innovation through Research and Development initiatives, focusing on developing next-generation devices and therapies. The increasing prevalence of retinal diseases in the US has created immense opportunities for these companies, enabling them to invest in novel solutions and expand their market position. Additionally, the "Others" segment, encompassing various specialized clinics and research institutions, holds potential through niche offerings and tailored services that cater to patient-specific needs. Overall, the interplay among these end users shapes the landscape of the US Artificial Retina Market, driven by advancements in technology, rising awareness about retinal health, and growing opportunities for surgical interventions and device development. ## **US Artificial Retina Market Key Players and Competitive Insights** The US Artificial Retina Market has garnered significant attention in recent years, primarily driven by advancements in technology and rising incidences of retinal diseases among the aging population. This sector is characterized by a variety of companies actively engaged in the development and commercialization of innovative retinal implants aimed at restoring vision. The competitive landscape is shaped by firms ranging from well-established corporations to emerging startups that specialize in groundbreaking technologies. These players are continually striving to differentiate themselves through unique product offerings, robust research and development initiatives, and strategic partnerships. The understanding of patient needs and preferences also shapes their competitive strategies as they navigate the complexities of regulatory approvals and reimbursement landscapes. Bionic Sight has emerged as a notable player in the US Artificial Retina Market, with a strong focus on developing advanced retinal implants that address visual impairments. The company has made significant strides in the enhancement of visual capabilities for patients suffering from retinal degenerative diseases. Bionic Sight is recognized for its innovative design integrating microelectronic systems with biological components, which helps improve the efficacy and functionality of its products. The strength of Bionic Sight lies in its strong commitment to research and development, allowing for ongoing innovations that adapt to the evolving needs of patients. Additionally, the company has built a solid reputation for collaboration with research institutions and its focus on clinical trials that bolster its credibility and market presence, facilitating deeper penetration into the competitive landscape. REGENETEK has carved out a unique niche within the US Artificial Retina Market through its comprehensive suite of products and services aimed at enhancing retinal health. The company primarily focuses on developing retinal prostheses designed for individuals with severe vision impairment. REGENETEK's strengths are anchored in its extensive research background and innovative technology that has been successfully brought to clinical applications. This company has leveraged strategic mergers and acquisitions to bolster its capabilities and expand its product portfolio, providing a competitive edge in the market. By bringing together expertise from different fields, REGENETEK has enhanced its ability to deliver quality solutions that meet diverse patient needs. Its focus on regulatory compliance and patient-centric approaches has further solidified its position in the US market, making it a formidable competitor as it continues to adapt and grow within this dynamic sector. ### **Key Companies in the US Artificial Retina Market Include** ## **US Artificial Retina Market Industry Developments** The US Artificial Retina Market has seen several notable developments recently. As of September 2023, Second Sight Medical Products announced advancements in their Argus II Retinal Prosthesis System, which has been receiving attention for its innovative approach to restoring vision in patients with retinitis pigmentosa. Additionally, in October 2023, they received FDA clearance for an upgraded version of their device that promises enhanced performance. Meanwhile, Regeneron Pharmaceuticals has reported significant growth in its vision-related therapies, positioning itself favorably in the market. In terms of mergers and acquisitions, no recent transactions involving Bionic Sight, NanoRetina, or other targeted companies have been publicly disclosed in the last few months. However, industry trends suggest an increasing focus on collaborative agreements and partnerships to advance Research and Development initiatives. In the last two to three years, the market has expanded significantly, attributed to technological improvements and increased funding from government and private sectors. This growth is further energized by a rising prevalence of retinal diseases among the aging population in the United States, which is projected to lead to heightened demand for artificial retina solutions. ## **US Artificial Retina Market Segmentation Insights** ### **Artificial Retina Market Product Outlook** ### **Artificial Retina Market Application Outlook** ### **Artificial Retina Market End User Outlook** ## Market Drivers ### Growing Awareness of Vision Health The increasing awareness of vision health among the US population is a notable driver for the artificial retina market. Public health campaigns and educational initiatives are emphasizing the importance of regular eye examinations and early detection of retinal diseases. As individuals become more informed about the risks associated with vision loss, there is a corresponding rise in demand for advanced treatment options, including artificial retina devices. This heightened awareness is likely to lead to earlier diagnoses and increased patient engagement in treatment decisions. Consequently, the artificial retina market may experience growth as more patients seek out innovative solutions to preserve and restore their vision. Healthcare providers are also adapting to this trend by incorporating discussions about artificial retina technologies into their patient care protocols. ### Increased Funding for Vision Research The artificial retina market is benefiting from increased funding for vision research in the US. Government agencies, private foundations, and venture capitalists are recognizing the potential of artificial retina technologies to address unmet medical needs. In recent years, funding for retinal research has surged, with millions of dollars allocated to projects aimed at developing innovative solutions for vision restoration. This financial support is crucial for advancing clinical trials and bringing new products to market. As a result, the artificial retina market is likely to see a rise in the number of viable products, enhancing competition and driving down costs for consumers. The influx of capital into this sector may also lead to collaborations between academic institutions and industry players, further accelerating the pace of innovation. ### Rising Incidence of Retinal Disorders The increasing prevalence of retinal disorders in the US is a primary driver for the artificial retina market. Conditions such as age-related macular degeneration (AMD) and retinitis pigmentosa are becoming more common, affecting millions of individuals. According to recent estimates, AMD alone impacts approximately 2.1 million people aged 50 and older in the US. This growing patient population necessitates innovative treatment options, thereby propelling demand for artificial retina technologies. As healthcare providers seek effective solutions to address these conditions, the artificial retina market is likely to experience substantial growth. The potential for improved patient outcomes through advanced retinal implants further enhances the attractiveness of this market. Stakeholders aim to invest in cutting-edge technologies that can restore vision and improve quality of life for affected individuals. ### Collaborations Between Industry and Academia Collaborations between industry and academic institutions are emerging as a significant driver for the artificial retina market. These partnerships facilitate the exchange of knowledge and resources, leading to accelerated innovation in retinal technologies. Universities and research centers often possess cutting-edge research capabilities, while industry players bring expertise in product development and commercialization. Such collaborations can result in the rapid translation of research findings into practical applications, enhancing the artificial retina market's growth potential. Furthermore, joint ventures may attract additional funding and resources, enabling the development of more sophisticated devices. As these partnerships continue to flourish, the artificial retina market is likely to benefit from a steady stream of innovative products that address the needs of patients with retinal disorders. ### Technological Innovations in Vision Restoration Technological advancements in vision restoration are significantly influencing the artificial retina market. Innovations such as wireless communication systems, improved biocompatibility of materials, and enhanced image processing algorithms are paving the way for more effective artificial retina devices. For instance, recent developments in microelectronic systems have led to the creation of devices that can interface directly with retinal cells, potentially improving visual acuity for users. The market is projected to grow at a CAGR of around 15% over the next five years, driven by these technological breakthroughs. As research institutions and companies continue to invest in R&D, the artificial retina market is expected to expand, offering new solutions that could transform the lives of individuals with vision impairments. ## Future Outlook The [Artificial Retina Market](https://www.marketresearchfuture.com/reports/artificial-retina-market-2812) is projected to grow at 8.41% CAGR from 2025 to 2035, driven by technological advancements, increasing prevalence of retinal diseases, and rising healthcare investments. **New opportunities:** - Development of advanced biocompatible materials for improved device longevity. Partnerships with healthcare providers for integrated patient management solutions. Expansion into emerging markets with tailored pricing strategies. By 2035, the artificial retina market is expected to achieve substantial growth, driven by innovation and strategic partnerships. ## Segment Insights ### By Type: Epiretinal Implants (Largest) vs. Suprachoroidal Implants (Fastest-Growing) In the US artificial retina market, Epiretinal Implants hold the largest market share among the various types, owing to their established presence and proven efficacy for treating vision loss related to retinal diseases. This segment has garnered significant attention from healthcare providers and patients alike, leading to wider acceptance and increased usage within clinical settings. Conversely, Suprachoroidal Implants are emerging as a fast-growing segment due to their innovative design and minimal invasiveness compared to traditional methods, attracting investment and interest from manufacturers. Growth trends indicate a strong upward trajectory for both Epiretinal and Suprachoroidal Implants. The rising incidence of retinal degenerative disorders significantly drives demand for effective solutions. Technological advancements, such as improved implantation techniques and enhanced biocompatibility of materials, further support the growth of Suprachoroidal Implants as a viable alternative, while regulatory approvals and successful clinical outcomes continue to reinforce the position of Epiretinal Implants in the market. Epiretinal Implants (Dominant) vs. Suprachoroidal Implants (Emerging) Epiretinal Implants are considered the dominant force in the US artificial retina market, primarily due to their proven effectiveness in restoring vision for patients suffering from conditions such as age-related macular degeneration and retinitis pigmentosa. Their established clinical track record and high level of patient acceptance contribute to significant market share. In contrast, Suprachoroidal Implants are emerging as a significant alternative, offering benefits such as a less invasive implantation approach and potentially lower complication rates. This innovative segment is gaining traction amid ongoing research and development efforts, positioning it for future growth as technology advances and more trials demonstrate favorable results. ### By Application: AMD (Largest) vs. Retinitis Pigmentosa (Fastest-Growing) In the US artificial retina market, Age-Related Macular Degeneration (AMD) holds the largest share, primarily due to its widespread prevalence among the aging population. This segment accounts for a significant portion of the total market, driven by the increasing number of elderly individuals and the rising recognition of AMD as a leading cause of visual impairment. Conversely, Retinitis Pigmentosa, while currently smaller in market share, is gaining traction as a fast-growing segment, owing to advancements in treatment and technologies specifically targeting this degenerative condition. Growth trends in this segment are propelled by continuous research and development aimed at enhancing treatment efficacy for AMD, alongside emerging therapies for Retinitis Pigmentosa. The increasing focus on personalized medicine is contributing to the rapid innovations within both segments. Moreover, the growing awareness and diagnosis of these conditions are prompting further investments into artificial retina solutions, fueling market expansion and attracting attention from key stakeholders in the healthcare industry. AMD (Dominant) vs. Retinitis Pigmentosa (Emerging) Age-Related Macular Degeneration (AMD) is the dominant application segment in the US artificial retina market, characterized by extensive clinical research and established treatment protocols that cater to a broad patient demographic. Its prominence is supported by a mature infrastructure for diagnosis and management, alongside a strong pipeline of innovative therapies. On the other hand, Retinitis Pigmentosa is emerging as a crucial segment, characterized by a smaller yet growing patient base. The increasing surges in clinical trials targeting this condition are indicative of a shift towards innovative solutions, highlighting the potential for breakthroughs in treatment. This segment is marked by a commitment to uncovering gene therapy and other advanced therapies, winning significant interest from both investors and researchers. ## Competitive Benchmarking The artificial retina market is currently characterized by a dynamic competitive landscape, driven by technological advancements and increasing demand for innovative solutions to address vision impairment. Key players such as Second Sight Medical Products (US), Abbott Laboratories (US), and Pixium Vision (FR) are at the forefront, each adopting distinct strategies to enhance their market positioning. Second Sight Medical Products (US) focuses on innovation through the development of advanced retinal prostheses, while Abbott Laboratories (US) emphasizes strategic partnerships to expand its product offerings. Pixium Vision (FR) is actively pursuing regional expansion, particularly in North America, to capitalize on the growing market potential. Collectively, these strategies contribute to a competitive environment that is increasingly focused on technological differentiation and market penetration.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market structure appears moderately fragmented, with several players vying for market share. However, the influence of key players is substantial, as they leverage their technological capabilities and market knowledge to shape industry standards and consumer expectations. In October Second Sight Medical Products (US) announced a collaboration with a leading research institution to develop next-generation retinal implants. This strategic move is likely to enhance their R&D capabilities and accelerate the introduction of innovative products, thereby strengthening their competitive edge in the market. The partnership underscores the importance of collaboration in driving technological advancements in the artificial retina sector. In September Abbott Laboratories (US) launched a new line of retinal implants designed to improve visual acuity in patients with degenerative eye diseases. This product introduction not only diversifies their portfolio but also positions Abbott as a key player in addressing unmet medical needs. The strategic importance of this launch lies in its potential to capture a larger market share and enhance patient outcomes, thereby reinforcing Abbott's commitment to innovation in healthcare. In August Pixium Vision (FR) secured a significant investment to fund its expansion efforts in the US market. This financial backing is expected to facilitate the development of new technologies and enhance their marketing strategies. The investment reflects a growing confidence in Pixium's potential to disrupt the market with innovative solutions, further intensifying competition among existing players. As of November current trends in the artificial retina market indicate a strong emphasis on digitalization, sustainability, and the integration of artificial intelligence (AI) in product development. Strategic alliances are increasingly shaping the competitive landscape, as companies recognize the value of collaboration in fostering innovation. Looking ahead, competitive differentiation is likely to evolve, with a shift from price-based competition to a focus on technological innovation, reliability in supply chains, and enhanced patient outcomes. This transition suggests that companies that prioritize R&D and strategic partnerships will be better positioned to thrive in the evolving market. ## Recent News & Developments The US Artificial Retina Market has seen several notable developments recently. As of September 2023, Second Sight Medical Products announced advancements in their Argus II Retinal Prosthesis System, which has been receiving attention for its innovative approach to restoring vision in patients with retinitis pigmentosa. Additionally, in October 2023, they received FDA clearance for an upgraded version of their device that promises enhanced performance. Meanwhile, Regeneron Pharmaceuticals has reported significant growth in its vision-related therapies, positioning itself favorably in the market. In terms of mergers and acquisitions, no recent transactions involving Bionic Sight, NanoRetina, or other targeted companies have been publicly disclosed in the last few months. However, industry trends suggest an increasing focus on collaborative agreements and partnerships to advance Research and Development initiatives. In the last two to three years, the market has expanded significantly, attributed to technological improvements and increased funding from government and private sectors. This growth is further energized by a rising prevalence of retinal diseases among the aging population in the United States, which is projected to lead to heightened demand for artificial retina solutions. ## Report Scope | MARKET SIZE 2024 | 501.29(USD Million) | | --- | --- | | MARKET SIZE 2025 | 543.45(USD Million) | | MARKET SIZE 2035 | 1218.81(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 8.41% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Second Sight Medical Products (US), Pixium Vision (FR), Bionic Vision Technologies (AU), Retina Implant AG (DE), Elekta (SE), Nidek Co Ltd (JP), Abbott Laboratories (US), Alcon (CH) | | Segments Covered | Type, Application | | Key Market Opportunities | Advancements in neuroprosthetics enhance visual restoration potential in the artificial retina market. | | Key Market Dynamics | Technological advancements drive innovation in artificial retina solutions, enhancing patient outcomes and market competitiveness. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the market valuation of the US artificial retina market in 2024?** A: The market valuation was $501.29 Million in 2024. **Q: What is the projected market valuation for the US artificial retina market by 2035?** A: The projected market valuation for 2035 is $1218.81 Million. **Q: What is the expected CAGR for the US artificial retina market during the forecast period 2025 - 2035?** A: The expected CAGR during the forecast period 2025 - 2035 is 8.41%. **Q: Which segment had the highest valuation in 2024 within the US artificial retina market?** A: The Subretinal Implants segment had the highest valuation at $200.45 Million in 2024. **Q: What are the projected valuations for Epiretinal Implants by 2035?** A: The projected valuation for Epiretinal Implants by 2035 is $364.2 Million. **Q: Which application segment is expected to dominate the US artificial retina market by 2035?** A: The Age-Related Macular Degeneration (AMD) application segment is expected to dominate with a projected valuation of $700.0 Million by 2035. **Q: Who are the key players in the US artificial retina market?** A: Key players include Second Sight Medical Products, Pixium Vision, Bionic Vision Technologies, and Abbott Laboratories. **Q: What was the valuation of the Retinitis Pigmentosa application segment in 2024?** A: The valuation of the Retinitis Pigmentosa application segment was $201.29 Million in 2024. **Q: What is the projected growth for the Suprachoroidal Implants segment by 2035?** A: The projected growth for the Suprachoroidal Implants segment by 2035 is to $372.61 Million. **Q: How does the market valuation of the US artificial retina market in 2024 compare to the projected valuation in 2035?** A: The market valuation in 2024 was $501.29 Million, which is expected to grow to $1218.81 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-artificial-retina-market-18985*